Aurobindo Pharma Limited has received final approval from the US Food & Drug Administration (FDA) to manufacture and market dexmedetomidine hydrochloride in 0.9% sodium chloride injection, 200 µg/50 mL and 400 µg/100 mL single dose flexible containers (bags).Aurobindo's dexmedetomidine HCl in 0.9% sodium chloride injection is a therapeutic equivalent generic version of Hospira's Precedex in 0.9% sodium chloride injection.The product will be launched in January 2021.Dexmedetomidine hydrochloride in 0.9% sodium chloride injection is a relatively selective alpha2 - adrenergic agonist indicated for a) sedation of initially intubated and mechanically ventilated patients during treatment in an intensive care setting; b) sedation of non-intubated patients prior to and/or during surgical and other procedures.The approved product has an estimated market size of US$ 228 million for the twelve months ending October 2020, according to IQVIA.This is the 79th ANDA to be approved out of Unit IV formulation facility in Hyderabad, India used for manufacturing injectable & ophthalmic products.Aurobindo now has a total of 459 ANDA approvals (431 Final approvals and 28 tentative approvals) from US FDA.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!